BRISBANE, Calif.--(BUSINESS WIRE)--May 1, 2019--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host a conference call on Wednesday, May 8, 2019,
at 4:30 p.m. ET to discuss its financial results for the quarter ended
March 31, 2019, and recent operational highlights.
To access the live call by phone, dial (877) 497-1438 (domestic) or
(262) 558-6296 (international) and enter the passcode 5667779. To access
a live or recorded webcast of the call, please visit the Investor
Relations section of the Aimmune Therapeutics website at www.aimmune.com.
The recorded webcast will be available for approximately 30 days
following the call.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing
oral treatments for life-threatening food allergies. The company’s Characterized
(CODIT™) approach is intended to provide meaningful levels of protection
against allergic reactions resulting from accidental exposure to food
allergens by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational biologic product, AR101, is
being developed as a treatment to reduce the risk of anaphylaxis
following accidental exposures to peanut. The BLA for AR101 is under
review by the FDA, which in 2015 granted AR101 Breakthrough Therapy
Designation for the desensitization of peanut-allergic patients 4 to 17
years of age. Aimmune expects to file for marketing approval of AR101 in
Europe in mid-2019. Aimmune has filed an IND application for its second
product, AR201 for the treatment of egg allergy, and intends to start a
randomized phase 2 clinical trial in mid-2019. For more information,
please see www.aimmune.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190501005361/en/
Source: Aimmune Therapeutics, Inc.
Eric Bjerkholt, 650-376-5582
Jerica Pitts, 312-858-3469